Vir Biotechnology, Inc.
VIR
$6.12
-$0.17-2.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 419.92% | -22.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 419.92% | -22.60% | |||
| Cost of Revenue | -54.52% | 85.64% | |||
| Gross Profit | 60.38% | -88.90% | |||
| SG&A Expenses | 3.72% | -14.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -47.74% | 63.16% | |||
| Operating Income | 52.83% | -65.16% | |||
| Income Before Tax | 50.98% | -52.65% | |||
| Income Tax Expenses | -148.59% | 111.71% | |||
| Earnings from Continuing Operations | 51.06% | -54.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 51.06% | -54.44% | |||
| EBIT | 52.83% | -65.16% | |||
| EBITDA | 53.53% | -68.39% | |||
| EPS Basic | 51.12% | -53.97% | |||
| Normalized Basic EPS | 55.75% | -76.55% | |||
| EPS Diluted | 51.12% | -53.97% | |||
| Normalized Diluted EPS | 55.75% | -76.55% | |||
| Average Basic Shares Outstanding | 0.11% | 0.31% | |||
| Average Diluted Shares Outstanding | 0.11% | 0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||